- Codeine Phosphate
- Codeine Sulfate
Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product
Solution, Oral, as sulfate:
Generic: 30 mg/5 mL (500 mL [DSC])
Tablet, Oral, as sulfate:
Generic: 15 mg, 30 mg, 60 mg
- Analgesic, Opioid
Binds to opioid receptors in the CNS, causing inhibition of ascending pain pathways, altering the perception of and response to pain; causes cough suppression by direct central action in the medulla; produces generalized CNS depression
Hepatic via UGT2B7 and UGT2B4 to codeine-6-glucuronide, via CYP2D6 to morphine (active), and via CYP3A4 to norcodeine. Morphine is further metabolized via glucuronidation to morphine-3-glucuronide and morphine-6-glucuronide (active).
Urine (~90%, ~10% of the total dose as unchanged drug); feces
Onset of Action
Oral: Immediate release: 0.5-1 hour; Peak effect: Oral: Immediate release: 1-1.5 hours
Time to Peak
Plasma: Immediate release: 1 hour; Controlled release [Canadian product]: 3.3 hours
Duration of Action
Immediate release: 4-6 hours
~7% to 25%
Use: Labeled Indications
Pain: Management of mild-to-moderately-severe pain
Cough: Canadian labeling: Additional use (not in US labeling): Relief of exhausting, nonproductive cough which does not respond to nonopioid antitussives
Short-term relief of cough in select patients
Hypersensitivity to codeine or any component of the formulation; respiratory depression in the absence of resuscitative equipment; acute or severe bronchial asthma or hypercarbia; presence or suspicion of paralytic ileus; postoperative pain management in children who have undergone tonsillectomy and/or adenoidectomy
Canadian labeling: Additional contraindications (not in US labeling): Hypersensitivity to other opioid analgesics; cor pulmonale; acute alcoholism; delirium tremens; severe CNS depression; convulsive disorders; increased cerebrospinal or intracranial pressure; head injury; obstructive airway disease (in addition to asthma); known or suspected mechanical GI obstruction or any disease that affects bowel transit; suspected surgical abdomen (eg, acute appendicitis or pancreatitis); use with or within 14 days of MAO inhibitors; pregnancy and during labor and delivery; children <12 years of age; Additional product specific contraindications: Codeine Contin: acute pain; intermittent or short duration pain that can be managed with alternative pain medication; breast-feeding
Immediate release tablet: 15 mg to 30 mg every 6 to 8 hours as needed (maximum: 120 mg/day).
Oral solution: 5 mL (25 mg) every 6 to 8 hours as needed.
Alternative recommendation (off-label use in US): Reported doses vary; range: 7.5 to 120 mg/day as a single dose or in divided doses (Bolser 2006; Smith 2010); Note: The American College of Chest Physicians does not recommend the routine use of codeine as an antitussive in patients with upper respiratory infections (Bolser 2006).
Pain management (analgesic): Oral: Note: These are guidelines and do not represent the maximum doses that may be required in all patients. Doses should be titrated to pain relief/prevention.
Immediate release (tablet, oral solution): Initial: 15 to 60 mg every 4 hours as needed; maximum total daily dose: 360 mg/day; patients with prior opioid exposure may require higher initial doses. Note: The American Pain Society recommends an initial dose of 30 to 60 mg for adults with moderate pain (American Pain Society 2008).
Controlled release: Codeine Contin [Canadian product]: Note: Titrate at intervals of ≥48 hours until adequate analgesia has been achieved. Daily doses >600 mg/day should not be used; patients requiring higher doses should be switched to an opioid approved for use in severe pain. In patients who receive both Codeine Contin and an immediate release or combination codeine product for breakthrough pain, the rescue dose of immediate release codeine product should be ≤12.5% of the total daily Codeine Contin dose.
Opioid-naive patients: Initial: 50 mg every 12 hours
Conversion from immediate release codeine preparations: Immediate release codeine preparations contain ~75% codeine base. Therefore, patients who are switching from immediate release codeine preparations may be transferred to a ~25% lower total daily dose of Codeine Contin, equally divided into 2 daily doses every 12 hours.
Conversion from a combination codeine product (eg, codeine with acetaminophen or aspirin): See table:
Number of 30 mg Codeine Combination Tablets Daily
Initial Dose of Codeine Contin
Maintenance Dose of Codeine Contin
50 mg every 12 h
100 mg every 12 h
100 mg every 12 h
150 mg every 12 h
150 mg every 12 h
200 mg every 12 h
200 mg every 12 h
200-300 every 12 h (maximum: 300 mg every 12 h)
Table has been converted to the following text.
Number of 30 mg codeine combination tablets daily: ≤6 tablets/day
Initial dose of Codeine Contin: 50 mg every 12 hours
Maintenance dose of Codeine Contin: 100 mg every 12 hours
Number of 30 mg codeine combination tablets daily: 7-9 tablets/day
Initial dose of Codeine Contin: 100 mg every 12 hours
Maintenance dose of Codeine Contin: 150 mg every 12 hours
Number of 30 mg codeine combination tablets daily: 10-12 tablets/day
Initial dose of Codeine Contin: 150 mg every 12 hours
Maintenance dose of Codeine Contin: 200 mg every 12 hours
Number of 30 mg codeine combination tablets daily: >12 tablets/day
Initial dose of Codeine Contin: 200 mg every 12 hours
Maintenance dose of Codeine Contin: 200-300 mg every 12 hours (maximum: 300 mg every 12 hours)
Conversion from another opioid analgesic: Using the patient’s current opioid dose, calculate an equivalent daily dose of immediate release codeine. A ~25% lower dose of Codeine Contin should then be initiated, equally divided into 2 daily doses.
Discontinuation of therapy: Note: Gradual dose reduction is recommended if clinically appropriate. Initially reduce the total daily dose by 50% and administer equally divided into 2 daily doses for 2 days followed by a 25% reduction every 2 days thereafter.
Refer to adult dosing. Use with caution and consider initiation at the low end of the dosing range; reduced initial dosages may be necessary.
Cough: Canadian labeling: Children ≥12 years and Adolescents: Oral: Refer to adult dosing.
Pain management (analgesic): Oral: Note: These are guidelines and do not represent the maximum doses that may be required in all patients. Doses should be titrated to pain relief/prevention.)
Canadian labeling: Children ≥12 years and Adolescents:
Immediate release (tablet, oral solution): Refer to adult dosing.
Controlled release: Use is not recommended (has not been studied)
Alternative recommendations (off-label use in US): Immediate release (tablet, oral solution): Initial: 0.5 to 1 mg/kg/dose every 4 hours as needed; maximum: 60 mg/dose (American Pain Society 2008)
Dosing: Renal Impairment
US labeling: There are no specific dosage adjustments provided in the manufacturers labeling; however, clearance may be reduced; active metabolites may accumulate. Initiate at lower doses or longer dosing intervals followed by careful titration.
Immediate release (tablet, oral solution):
CrCl >50 mL/minute: No dosage adjustment necessary.
CrCl 10 to 50 mL/minute: Administer 75% of dose and titrate carefully as needed.
CrCl <10 mL/minute: Administer 50% of dose and titrate carefully as needed.
Controlled release: There are no dosage adjustments provided in the manufacturer labeling; however, a reduced dosage is recommended
Alternate recommendations: The following guidelines have been used by some clinicians (Aronoff 2007):
CrCl 10 to 50 mL/minute: Administer 75% of dose
CrCl <10 mL/minute: Administer 50% of dose
Dosing: Hepatic Impairment
There are no dosage adjustments provided in the manufacturer’s labeling (has not been studied); however, initial lower doses or longer dosing intervals followed by careful titration are recommended.
A 3 mg/mL oral suspension may be made with codeine phosphate powder, USP. Add 600 mg of powder to a 400 mL beaker. Add 2.5 mL of Sterile Water for Irrigation, USP, and stir to dissolve the powder. Mix for 10 minutes while adding Ora-Sweet to make 200 mL; transfer to a calibrated bottle. Stable 98 days at room temperature.Dentinger PJ and Swenson CF, "Stability of Codeine Phosphate in an Extemporaneously Compounded Syrup," Am J Health Syst Pharm, 2007, 64(24):2569-73.18056945
May administer without regard to meals. Take with food or milk to decrease adverse GI effects.
Controlled release tablets: Codeine Contin [Canadian product]: Tablets should be swallowed whole; do not chew, dissolve, or crush. All strengths may be halved, except the 50 mg tablets; half tablets should also be swallowed intact.
Immediate release tablet, oral solution: Store at 15°C to 30°C (59°F to 86°F). Protect from moisture and light.
Controlled release tablet [Canadian product]: Store at 15°C to 30°C (59°F to 86°F).
Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl). Monitor therapy
Alvimopan: Analgesics (Opioid) may enhance the adverse/toxic effect of Alvimopan. This is most notable for patients receiving long-term (i.e., more than 7 days) opiates prior to alvimopan initiation. Management: Alvimopan is contraindicated in patients receiving therapeutic doses of opioids for more than 7 consecutive days immediately prior to alvimopan initiation. Consider therapy modification
Ammonium Chloride: May increase the excretion of Analgesics (Opioid). Monitor therapy
Amphetamines: May enhance the analgesic effect of Analgesics (Opioid). Monitor therapy
Anticholinergic Agents: May enhance the adverse/toxic effect of Analgesics (Opioid). Specifically, the risk for constipation and urinary retention may be increased with this combination. Monitor therapy
Antipsychotic Agents (Phenothiazines): May enhance the hypotensive effect of Analgesics (Opioid). Monitor therapy
Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal). Avoid combination
Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin. Consider therapy modification
Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants. Monitor therapy
Cannabis: May enhance the CNS depressant effect of CNS Depressants. Monitor therapy
CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants. Exceptions: Levocabastine (Nasal). Monitor therapy
CYP2D6 Inhibitors (Moderate): May diminish the therapeutic effect of Codeine. These CYP2D6 inhibitors may prevent the metabolic conversion of codeine to its active metabolite morphine. Monitor therapy
CYP2D6 Inhibitors (Strong): May diminish the therapeutic effect of Codeine. These CYP2D6 inhibitors may prevent the metabolic conversion of codeine to its active metabolite morphine. Consider therapy modification
Desmopressin: Analgesics (Opioid) may enhance the adverse/toxic effect of Desmopressin. Monitor therapy
Diuretics: Analgesics (Opioid) may enhance the adverse/toxic effect of Diuretics. Monitor therapy
Doxylamine: May enhance the CNS depressant effect of CNS Depressants. Management: The manufacturer of Diclegis (doxylamine/pyridoxine), intended for use in pregnancy, specifically states that use with other CNS depressants is not recommended. Monitor therapy
Dronabinol: May enhance the CNS depressant effect of CNS Depressants. Monitor therapy
Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use. Consider therapy modification
Eluxadoline: Analgesics (Opioid) may enhance the constipating effect of Eluxadoline. Avoid combination
Hydrocodone: CNS Depressants may enhance the CNS depressant effect of Hydrocodone. Management: Consider starting with a 20% to 30% lower hydrocodone dose when using together with any other CNS depressant. Dose reductions in the other CNS depressant may also be warranted. Consider therapy modification
HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants. Monitor therapy
Kava Kava: May enhance the adverse/toxic effect of CNS Depressants. Monitor therapy
Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants. Monitor therapy
Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants. Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established. Consider therapy modification
Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine. Monitor therapy
Minocycline: May enhance the CNS depressant effect of CNS Depressants. Monitor therapy
Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine. Monitor therapy
Mixed Agonist / Antagonist Opioids: May diminish the analgesic effect of Analgesics (Opioid). Management: Seek alternatives to mixed agonist/antagonist opioids in patients receiving pure opioid agonists, and monitor for symptoms of therapeutic failure/high dose requirements (or withdrawal in opioid-dependent patients) if patients receive these combinations. Avoid combination
Nabilone: May enhance the CNS depressant effect of CNS Depressants. Monitor therapy
Naltrexone: May diminish the therapeutic effect of Analgesics (Opioid). Management: Seek therapeutic alternatives to opioids. See full drug interaction monograph for detailed recommendations. Consider therapy modification
Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. Avoid combination
OxyCODONE: CNS Depressants may enhance the CNS depressant effect of OxyCODONE. Management: When oxycodone is combined with another CNS depressant, a dose reduction of one or both agents should be considered. The extended release oxycodone starting dose should be reduced 50% to 67% when initiated in patients already receiving CNS depressants. Consider therapy modification
Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. Avoid combination
Pegvisomant: Analgesics (Opioid) may diminish the therapeutic effect of Pegvisomant. Monitor therapy
Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination. Consider therapy modification
Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole. Monitor therapy
Ramosetron: Analgesics (Opioid) may enhance the constipating effect of Ramosetron. Monitor therapy
ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole. Monitor therapy
Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine. Monitor therapy
Rufinamide: May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced. Monitor therapy
Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced. Monitor therapy
Serotonin Modulators: Analgesics (Opioid) may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome. Monitor therapy
Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated. Consider therapy modification
Somatostatin Analogs: May decrease the metabolism of Codeine. The formation of two major codeine metabolites (morphine and norcodeine) may be impaired by somatostatin analogs. Monitor therapy
Succinylcholine: May enhance the bradycardic effect of Analgesics (Opioid). Monitor therapy
Suvorexant: CNS Depressants may enhance the CNS depressant effect of Suvorexant. Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary. Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended. Consider therapy modification
Tapentadol: May enhance the CNS depressant effect of CNS Depressants. Management: Start tapentadol at a dose of one-third to one-half of the normal dose if being initiated in a patient who is taking another drug with CNS depressant effects. Monitor closely for evidence of excessive CNS depression. Consider therapy modification
Tetrahydrocannabinol: May enhance the CNS depressant effect of CNS Depressants. Monitor therapy
Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. Avoid combination
Trimeprazine: May enhance the CNS depressant effect of CNS Depressants. Monitor therapy
Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem. Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for men who are also receiving other CNS depressants. No such dose change is recommended for women. Avoid use with other CNS depressants at bedtime; avoid use with alcohol. Consider therapy modification
Some quinolones may produce a false-positive urine screening result for opioids using commercially-available immunoassay kits. This has been demonstrated most consistently for levofloxacin and ofloxacin, but other quinolones have shown cross-reactivity in certain assay kits. Confirmation of positive opioid screens by more specific methods should be considered.
Frequency not defined.
Cardiovascular: Bradycardia, cardiac arrest, circulatory depression, flushing, hypertension, hypotension, palpitations, shock, syncope, tachycardia
Central nervous system: Abnormal dreams, agitation, anxiety, apprehension, ataxia, chills, depression, disorientation, dizziness, drowsiness, dysphoria, euphoria, fatigue, hallucination, headache, increased intracranial pressure, insomnia, nervousness, paresthesia, sedation, shakiness, taste disorder, vertigo
Dermatologic: Diaphoresis, pruritus, skin rash, urticaria
Gastrointestinal: Abdominal cramps, abdominal pain, anorexia, biliary tract spasm, constipation, diarrhea, nausea, pancreatitis, vomiting, xerostomia
Genitourinary: Urinary hesitancy, urinary retention
Hypersensitivity: Hypersensitivity reaction
Neuromuscular & skeletal: Laryngospasm, muscle rigidity, tremor, weakness
Ophthalmic: Blurred vision, diplopia, miosis, nystagmus, visual disturbance
Respiratory: Bronchospasm, dyspnea, respiratory arrest, respiratory depression
<1% (Limited to important or life-threatening): Hypogonadism (Brennan, 2013; Debono, 2011)
Concerns related to adverse effects:
• CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).
• Constipation: Use may cause or aggravate constipation; chronic use may result in obstructive bowel disease, particularly in those with underlying intestinal motility disorders. May also be problematic in patients with unstable angina and patients post-myocardial infarction. Consider preventative measures (eg, stool softener, increased fiber) to reduce the potential for constipation.
• Hypotension: May cause hypotension; use with caution in patients with hypovolemia, cardiovascular disease (including acute MI), or drugs which may exaggerate hypotensive effects (including phenothiazines or general anesthetics).
• Phenanthrene hypersensitivity: Use with caution in patients with hypersensitivity reactions to other phenanthrene-derivative opioid agonists (hydrocodone, hydromorphone, levorphanol, oxycodone, oxymorphone). The Canadian labeling contraindicates use in patients allergic to other opioids.
• Respiratory depression: May cause dose-related respiratory depression. The risk is increased in elderly patients, debilitated patients, and patients with conditions associated with hypoxia, hypercapnia, or upper airway obstruction.
• Abdominal conditions: May obscure diagnosis or clinical course of patients with acute abdominal conditions.
• Adrenal insufficiency: Use with caution in patients with adrenal insufficiency, including Addison disease. Long-term opioid use may cause secondary hypogonadism, which may lead to sexual dysfunction, infertility, mood disorders, and osteoporosis (Brennan 2013).
• Biliary tract impairment: Use with caution in patients with biliary tract dysfunction, including acute pancreatitis (use is contraindicated in the Canadian labeling); may cause constriction of sphincter of Oddi; may increase amylase/lipase levels.
• CNS depression/coma: Avoid use of codeine in patients with CNS depression or coma as these patients are susceptible to intracranial effects of CO2 retention.
• Drug abuse: Use with caution in patients with a history of drug abuse or acute alcoholism (use is contraindicated in the Canadian labeling); potential for drug dependency exists. Tolerance, psychological and physical dependence may occur with prolonged use.
• Gastrointestinal obstruction: Avoid use in patients with gastrointestinal obstruction, particularly paralytic ileus; chronic use may result in obstructive bowel disease.
• Head trauma: Use with extreme caution in patients with head injury, intracranial lesions, or elevated intracranial pressure (use is contraindicated in the Canadian labeling); exaggerated elevation of ICP may occur. May also interfere with pupillary response and consciousness, thereby, affecting neurologic examination.
• Hepatic impairment: Use with caution in patients with severe hepatic impairment.
• Obesity: Use with caution in patients who are morbidly obese.
• Prostatic hyperplasia/urinary stricture: Use with caution in patients with prostatic hyperplasia and/or urinary stricture.
• Renal impairment: Use with caution in patients with severe renal impairment.
• Respiratory disease: Use with caution in patients with preexisting respiratory compromise (hypoxia), COPD or other obstructive pulmonary disease, and kyphoscoliosis or other skeletal disorder which may alter respiratory function; critical respiratory depression may occur, even at therapeutic dosages.
• Seizure disorders: May induce or aggravate seizures; use with caution in patients with seizure disorders (use is contraindicated in the Canadian labeling).
• Thyroid dysfunction: Use with caution in patients with thyroid dysfunction.
Concurrent drug therapy issues:
• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.
• Sedatives: Effects may be potentiated when used with other sedative drugs or ethanol.
• CYP2D6 “ultrarapid metabolizers”: Use caution in patients with two or more copies of the variant CYP2D6*2 allele; may have extensive conversion to morphine and thus increased opioid-mediated effects. Avoid the use of codeine in these patients; consider alternative analgesics such as morphine or a nonopioid agent (Crews 2012). The occurrence of this phenotype is seen in 0.5% to 1% of Chinese and Japanese, 0.5% to 1% of Hispanics, 1% to 10% of Caucasians, 3% of African-Americans, and 16% to 28% of North Africans, Ethiopians, and Arabs.
• Debilitated patients: Use with caution in debilitated patients; there is a greater potential for critical respiratory depression, even at therapeutic dosages.
• Elderly: Use with caution in the elderly; may be more sensitive to adverse effects. Consider decreasing the initial dose.
• Neonates: Neonatal withdrawal syndrome: After chronic maternal exposure to opioids, neonatal withdrawal syndrome may occur in the newborn; monitor neonate closely. Signs and symptoms include irritability, hyperactivity and abnormal sleep pattern, high pitched cry, tremor, vomiting, diarrhea and failure to gain weight. Onset, duration and severity depend on the drug used, duration of use, maternal dose, and rate of drug elimination by the newborn. Opioid withdrawal syndrome in the neonate, unlike in adults, may be life-threatening and should be treated according to protocols developed by neonatology experts.
• Pediatric: [US Boxed Warning]: Respiratory depression and death have occurred in children who received codeine following tonsillectomy and/or adenoidectomy and were found to have evidence of being ultra-rapid metabolizers of codeine due to a CYP2D6 polymorphism. Deaths have also occurred in nursing infants after being exposed to high concentrations of morphine because the mothers were ultra-rapid metabolizers. Use is contraindicated in the postoperative pain management of children who have undergone tonsillectomy and/or adenoidectomy. The Canadian labeling contraindicates use in children <12 years of age.
Dosage form specific issues:
• Sulfites: Some preparations contain sulfites which may cause allergic reactions.
• Abuse/misuse/diversion: Healthcare provider should be alert to the potential for abuse, misuse, and diversion.
• Withdrawal: Concurrent use of agonist/antagonist analgesics may precipitate withdrawal symptoms and/or reduced analgesic efficacy in patients following prolonged therapy with mu opioid agonists. Abrupt discontinuation following prolonged use may also lead to withdrawal symptoms.
Pain relief, respiratory and mental status, blood pressure, heart rate; signs or symptoms of hypogonadism or hypoadrenalism (Brennan 2013)
Pregnancy Risk Factor
Adverse events have been observed in animal reproduction studies. Opioid analgesics cross the placenta. In humans, birth defects (including some heart defects) have been associated with maternal use of codeine during the first trimester of pregnancy (Broussard 2011). If chronic opioid exposure occurs in pregnancy, adverse events in the newborn (including withdrawal) may occur; monitoring of the neonate is recommended. The minimum effective dose should be used if opioids are needed (Chou 2009). Neonatal abstinence syndrome following opioid exposure may present with autonomic (eg, fever, temperature instability), gastrointestinal (eg, diarrhea, vomiting, poor feeding/weight gain), or neurologic (eg, high pitched crying, increased muscle tone, irritability, seizure, tremor) symptoms (Dow 2012; Hudak 2012).
• Discuss specific use of drug and side effects with patient as it relates to treatment. (HCAHPS: During this hospital stay, were you given any medicine that you had not taken before? Before giving you any new medicine, how often did hospital staff tell you what the medicine was for? How often did hospital staff describe possible side effects in a way you could understand?)
• Patient may experience fatigue or sweating a lot. Have patient report immediately to prescriber severe dizziness, passing out, angina, tachycardia, trouble breathing, slow breathing, shallow breathing, illogical thinking, arrhythmia, hallucinations, mood changes, seizures, severe abdominal pain, severe headache, difficult urination, tremors, vision changes, severe nausea, vomiting, severe constipation, or loss of strength and energy (HCAHPS).
• Educate patient about signs of a significant reaction (eg, wheezing; chest tightness; fever; itching; bad cough; blue skin color; seizures; or swelling of face, lips, tongue, or throat). Note: This is not a comprehensive list of all side effects. Patient should consult prescriber for additional questions.
Intended Use and Disclaimer: Should not be printed and given to patients. This information is intended to serve as a concise initial reference for healthcare professionals to use when discussing medications with a patient. You must ultimately rely on your own discretion, experience and judgment in diagnosing, treating and advising patients.
More about codeine
- Codeine (AHFS Monograph)
- Codeine Phosphate (AHFS Monograph)
- Codeine Sulfate (AHFS Monograph)
- Codeine Sulfate (FDA)
- Codeine Sulfate Oral Solution (FDA)